Bardia aditya
웹2024년 2월 11일 · Lauren Scarpetti, Chetan C Oturkar, Dejan Juric, Maria Shellock, Giuliana Malvarosa, Kathryn Post, Steven Isakoff, Nancy Wang, Brian Nahed, Kevin Oh, Gokul M Das, Aditya Bardia, Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53, The Oncologist, Volume 28, Issue 4, April … 웹Dr. Bardia is a board-certified medical oncologist interested in developing successful targeted and personalized therapies to improve the outcomes of patients and families afflicted with breast cancer. The accurate identification of target is crucial for success of targeted therapies, and Dr. Bardia is involved in the clinical development of tumor genotyping as well as …
Bardia aditya
Did you know?
웹I'm honored to share that I have been awarded the prestigious "EPAM Impact 2024" award from EPAM Systems I'm grateful for this recognition and would like to… LinkedIn 有 10 則回應 웹Aditya Bardia, M.D., MPH is a board-certified medical oncologist, an Attending Physician at Massachusetts General Hospital (MGH) Cancer Center, and Assistant Professor of Medicine at Harvard Medical School. As the Director of Precision Oncology Program at the MGH Center for Breast Cancer, Dr. Bardia has led the clinical development of the newly-approved …
웹Aditya Bardia's 544 research works with 17,837 citations and 4,037 reads, including: A Phase I Study of Adjuvant Niraparib Administered Concurrently with Postoperative Radiation … 웹2024년 11월 3일 · [iv] Bardia, Aditya, and Sara Hurvitz. 2024. "Targeted Therapy For Premenopausal Women With HR+, HER2− Advanced Breast Cancer: Focus On Special Considerations And Latest Advances". Clinical Cancer Research 24 (21): 5206-5218.
웹2024년 1월 27일 · Aditya Bardia, MD. @dradityabardia. FDA approves elacestrant, oral SERD, for ESR1-mutated ER+ metastatic breast cancer, based on phase 3 EMERALD … 웹Dr. Bardia is a board-certified medical oncologist interested in developing successful targeted and personalized therapies to improve the outcomes of patients and families afflicted with …
웹2024년 8월 5일 · Aditya Bardia 1 , Kathleen Harnden 2 , Lauren Mauro 2 , Angela Pennisi 2 , Melissa Armitage 3 , Hatem Soliman 3 4 Affiliations 1 Massachusetts General Hospital …
웹2024년 6월 27일 · Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate that contains the irinotecan active metabolite, SN-38, linked to a humanized monoclonal antibody targeting trophoblast cell surface antigen 2, which is overexpressed in many solid tumors. jester 3am halloween웹DEBUG & PROFILING (BoomBoom, Clever, Gear Studio, Glyph, Gravity, PAP, Telemetry) inspirahealthnetwork make appointment웹Bardia A, Mayer I, Winer E, Linden HM, Ma CX, Parker BA, et al. The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer. Breast Cancer Res Treat. 2024 Jan;197:319–31. dc.identifier.issn: 1573-7217: dc.identifier.uri inspira health network medical group웹Lloyd MR, Spring LM, Bardia A, Wander SA. Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clin Cancer Res. 2024 03 01; 28 (5):821-830. inspira health network mullica hill웹2024년 12월 9일 · 17. Bardia A, et al. ESMO 2024. Abstract 274TiP. P6-10-03. DatopotamabDeruxtecan(Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study • TROPION-PanTumor01 (NCT03401385) is a phase 1, multicenter, open-label, 2-part, dose-escalation and … inspira health network med grp pc웹2024년 8월 26일 · Aditya Bardia, MD, MPH, discussed final results from the phase 3 ASCENT study evaluating sacituzumab govitecan vs physician’s choice of single-agent chemotherapy for patients with relapsed or refractory metastatic triple-negative breast cancer. jester button worldhttp://mdedge.ma1.medscape.com/hematology-oncology/article/260049/metastatic-breast-cancer/high-response-rates-t-dxd-early-her2-low inspira health network life